ArticleNature communications2017
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Efficacy of pharmacological and microbiota-based therapies in preclinical models of autism spectrum disorder: a systematic review.Molecular psychiatry · 2026Pooled it
- Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease.Biomolecules · 2022Pooled it
- Hyperfunction of PSD-95 leads to hyperexcitability and cognitive abnormalities in MEF2C haploinsufficiency.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- An ASXL3-thyroid hormone axis in parvalbumin interneurons controls autism-like behaviors.Science advances · 2026Article
- The NO-cGMP signaling pathway and depression: mechanisms and therapeutic prospects.Molecular biology reports · 2026Review
- The comparative ameliorating effects of an amorphous formula of curcumin and α-glycosyl isoquercitrin on hippocampal dysfunction in a rat gulf war illness model.Metabolic brain disease · 2026Article
- MeCP2 Governs maternal hyperandrogenism-induced cortical defects and behavioral alterations via noncanonical AR-dependent regulation of Mef2c.Nature communications · 2026Article
- Conserved Cell-Type-Specific Transcriptomic Networks and Regulatory Programs Underlie Alcohol Dependence Across Mouse and Human.Research square · 2026Article
- High-throughput transcriptomic screening reveals entrectinib as a repositioning opportunity in 19q12 autism spectrum disorder.Scientific reports · 2025Article
- Transcriptional and epigenetic targets of MEF2C in human microglia contribute to cellular functions related to autism risk and age-related disease.Nature immunology · 2025Article
- Redox modulation of the complement cascade contributes to synapse loss in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Aberrant S-nitrosylation in the TCA cycle contributes to mitochondrial dysfunction, energy compromise, and synapse loss in neurodegenerative diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Non-Coding RNAs in Neurodevelopmental Disorders-From Diagnostic Biomarkers to Therapeutic Targets: A Systematic Review.Biomedicines · 2025Review
- Dysregulation of miRNA expression and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids.Molecular psychiatry · 2025Article
- Editorial: Cellular and molecular mechanisms that govern assembly, plasticity, and function of GABAergic inhibitory circuits in the mammalian brain.Frontiers in cellular neuroscience · 2025Article
- Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias.Neuron · 2024Review
- Article
- Developmental Disruption of Mef2c in Medial Ganglionic Eminence-Derived Cortical Inhibitory Interneurons Impairs Cellular and Circuit Function.Biological psychiatry · 2024Article
- Gating of Social Behavior by Inhibitory Inputs from Hippocampal CA1 to Retrosplenial Agranular Cortex.Neuroscience bulletin · 2024Article
- MEF2C Alleviates Postoperative Cognitive Dysfunction by Repressing Ferroptosis.CNS neuroscience & therapeutics · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 4 countries.
Shichun TuNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA. shichuntu@scintillon.org.
Mohd Waseem AkhtarNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.
Rosa Maria EscorihuelaNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Alejandro Amador-ArjonaNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Vivek SwarupCenter for Autism Research and Treatment (CART), University of California, Los Angeles, CA, 90095, USA.
James ParkerNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.ORCID http://orcid.org/0000-0002-1150-8374
Jeffrey D ZarembaNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.ORCID http://orcid.org/0000-0001-6531-5474
Timothy HollandNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Neha BansalNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Daniel R HolohanNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Kevin LopezNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.
Scott D RyanNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Shing Fai ChanNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Li YanNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Xiaofei ZhangNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Xiayu HuangBioinformatics Core Facility, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Abdullah SultanNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.
Scott R McKercherNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.
Rajesh AmbasudhanNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA.
Huaxi XuNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Yuqiang WangInstitute of New Drug Research, Jinan University College of Pharmacy, Guangzhou, 510632, China.
Daniel H GeschwindCenter for Autism Research and Treatment (CART), University of California, Los Angeles, CA, 90095, USA.
Amanda J RobertsDepartment of Neuroscience and Mouse Behavioral Assessment Core, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Alexey V TerskikhNeuroscience and Aging Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Robert A RissmanDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA, 92093, USA.
Eliezer MasliahDepartment of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, CA, 92093, USA.
Stuart A LiptonNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA. slipton@scripps.edu.
Nobuki NakanishiNeurodegenerative Disease Center, Scintillon Institute, San Diego, CA, 92121, USA. nnakanishi@scintillon.org.
Sanford Burnham Prebys Medical Discovery Institute · USScripps Research Institute · USUniversity of California, Los Angeles · USUniversity of California San Diego · USDiscovery Institute · USJinan University · CNUniversitat Autònoma de Barcelona · ES
Funding
PROJECT III - GENETIC APPROACH TO EXCITATORY TRANSMISSIONP01HD029587 · NICHD · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI LIPTON, STUART A · 1992 to 2016
$21.9MNovel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug AbuseDP1DA041722 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2016 to 2020
$7.0MProject-002P30NS076411 · NINDS · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI LIPTON, STUART A · 2011 to 2016
$4.5MDynamic Interactions of the S-Nitrosoproteome in Type 2 Diabetes/Metabolic Syndrome and Alzheimer’s DiseaseRF1AG057409 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2020
$4.1MS-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's DiseaseR01AG056259 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2021
$3.3MModeling Parkinson's Disease with Isogenic hiPSC-Derived Dopaminergic NeuronsR01NS086890 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2014 to 2018
$2.1MThe Role of DLG5 in Alzheimer's DiseaseR21AG048519 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI XU, HUAXI · 2015 to 2016
$536kAnti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimer’s Disease.R43AG055208 · NIA · ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS · PI TU, SHICHUN · 2016 to 2016
$225kGeneration and Characterization of Nanobodies Against beta-AmyloidR43AG052233 · NIA · ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS · PI TU, SHICHUN · 2015 to 2015
$225kNIA NIH HHS R01 AG056259NIA NIH HHS R21 AG048519NIA NIH HHS R43 AG052233NIA NIH HHS R43 AG055208NIA NIH HHS RF1 AG057409NICHD NIH HHS P01 HD029587NIDA NIH HHS DP1 DA041722NINDS NIH HHS P30 NS076411NINDS NIH HHS R01 NS086890
Abstract
Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy. However, molecular mechanisms underlying MEF2C haploinsufficiency syndrome remain poorly understood. Here we report that Mef2c
Indexed as
HaploinsufficiencyAnimalsAutistic DisorderBehavior, AnimalBiomarkersBrainCell DeathDisease Models, AnimalDown-RegulationExcitatory Amino Acid AntagonistsGene Expression ProfilingHumansLong-Term PotentiationMEF2 Transcription FactorsMemantineMice, Inbred C57BLBiomarkersExcitatory Amino Acid AntagonistsMef2c protein, mouseMEF2 Transcription FactorsMemantineReceptors, N-Methyl-D-Aspartate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.